Safety and efficacy of cathodal transcranial direct current stimulation in patients with Lennox Gastaut Syndrome: An open-label, prospective, single-center, single-blinded, pilot study

被引:2
|
作者
San-Juan, Daniel [1 ]
Ruiz, Axel Galindo [1 ]
Arriola, Armando Baigts [1 ]
Pesqueira, Gerardo Quinones [1 ]
Ruffini, Giulio [2 ]
Trenado, Carlos [3 ]
机构
[1] Natl Inst Neurol & Neurosurg Mexico, Dept Clin Neurophysiol, Mexico City, DF, Mexico
[2] Neuroelectrics Corp, Cambridge, MA USA
[3] Heinrich Heine Univ, Fac Med, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany
来源
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2022年 / 100卷
关键词
tDCS; Lennox Gastaut syndrome; Seizure; Epilepsy; Transcranial direct current stimulation; Refractory seizure; TEMPORAL-LOBE EPILEPSY; MOTOR CORTEX EXCITABILITY; SEIZURE FREQUENCY; DC POLARIZATION; TRIAL; FEASIBILITY; MODULATION; MECHANISMS; PLASTICITY; SHIFTS;
D O I
10.1016/j.seizure.2022.06.009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: Lennox-Gastaut Syndrome (SLG) is a severe form of childhood refractory epilepsy. Only one pilot study has been conducted using cathodal transcranial direct current stimulation (c-tDCs; 2mAx30minx5days) in LGS with promising results (-99% seizure reduction at 5 days). Our aim was to explore and replicate the efficacy and safety of 10 daily sessions of c-tDCs in SLG. Methods: We conducted a one-blinded, single-center pilot clinical study of c-tDCs (2mAx 30 min x 10 days), applied over the highest amplitude or frequent epileptiform interictal discharges areas using scalp EEG re-cordings without changes in their treatments. The tDCS device used was Enobio EEG (R) (Neuroelectrics, Barce-lona, Spain). The primary outcome was based on the seizure frequency using seizure diaries before, during 10 days of treatment, and then on a 4 and 8 weeks of follow-up. The rate of adverse events was recorded as a secondary outcome. Descriptive statistics and Wilcoxon signed-rank test were used Results: Twenty-four patients were enrolled. The mean age was 10.1 +/- 5.8 years old and 75% male. All the patients had severe mental retardation and abnormal neurological examinations. A significant median percentual seizure frequency reduction was found: 68.12% (p = 0.05) at 1 week, 68.12% (p = 0.002) in the second week. We found no significant reduction at 1 and 2 months; mainly tonic and atonic seizures were reduced significantly at all times. Only mild self-limited side effects were recorded mainly itching and erythema in the application zone Conclusion: Ten sessions of c-tDCs in combination with pharmacologic treatment in LGS is safe and appears to reduce significatively tonic and atonic seizure frequency at 2 months of follow-up.
引用
收藏
页码:44 / 50
页数:7
相关论文
共 50 条
  • [21] Efficacy of supplemental MCT oil on seizure reduction of adult drug-resistant epilepsy - a single-center open-label pilot study
    Rasmussen, Emmaline
    Patel, Vimal
    Tideman, Samuel
    Frech, Robert
    Frigerio, Roberta
    Narayanan, Jaishree
    NUTRITIONAL NEUROSCIENCE, 2023, 26 (06) : 535 - 539
  • [22] Treatment of chronic tinnitus with repeated sessions of prefrontal transcranial direct current stimulation: outcomes from an open-label pilot study
    Frank, Elmar
    Schecklmann, Martin
    Landgrebe, Michael
    Burger, Julia
    Kreuzer, Peter
    Poeppl, Timm B.
    Kleinjung, Tobias
    Hajak, Goran
    Langguth, Berthold
    JOURNAL OF NEUROLOGY, 2012, 259 (02) : 327 - 333
  • [23] Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability
    Foo, Eng Chuan
    Geldard, Jo
    Peacey, Caroline
    Wright, Elizabeth
    Eltayeb, Khalid
    Maguire, Melissa
    EPILEPSY & BEHAVIOR, 2019, 99
  • [24] Treatment of chronic tinnitus with repeated sessions of prefrontal transcranial direct current stimulation: outcomes from an open-label pilot study
    Elmar Frank
    Martin Schecklmann
    Michael Landgrebe
    Julia Burger
    Peter Kreuzer
    Timm B. Poeppl
    Tobias Kleinjung
    Göran Hajak
    Berthold Langguth
    Journal of Neurology, 2012, 259 : 327 - 333
  • [25] Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial
    Patel, Anup D.
    Mazurkiewicz-Beldzinska, Maria
    Chin, Richard F.
    Gil-Nagel, Antonio
    Gunning, Boudewijn
    Halford, Jonathan J.
    Mitchell, Wendy
    Scott Perry, Michael
    Thiele, Elizabeth A.
    Weinstock, Arie
    Dunayevich, Eduardo
    Checketts, Daniel
    Devinsky, Orrin
    EPILEPSIA, 2021, 62 (09) : 2228 - 2239
  • [26] Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial
    Ohtsuka, Yoko
    Yoshinaga, Harumi
    Shirasaka, Yukiyoshi
    Takayama, Rumiko
    Takano, Hiroki
    Iyoda, Kuniaki
    EPILEPSY RESEARCH, 2016, 121 : 1 - 7
  • [27] Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results of the Open-label Extension (OLE) Trial (GWPCARE5)
    Thiele, E.
    Marsh, E.
    Halford, J.
    Mazurkiewicz-Beldzinska, M.
    Gunning, B.
    Checketts, D.
    Roberts, C.
    ANNALS OF NEUROLOGY, 2018, 84 : S336 - S336
  • [28] Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
    Si, Tianmei
    Zhang, Kerang
    Tang, Jisheng
    Fang, Maosheng
    Li, Keqing
    Zhuo, Jianmin
    Feng, Yu
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1483 - 1492
  • [29] Effect of home-based transcranial direct current stimulation (tDCS) on cognitive functioning in bipolar depression: an open-label, single-arm acceptability and feasibility study
    Rezaei, Hakimeh
    Woodham, Rachel D.
    Ghazi-Noori, Ali-Reza
    Ritter, Philipp
    Bramon, Elvira
    Bauer, Michael
    Young, Allan H.
    Fu, Cynthia H. Y.
    INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS, 2025, 13 (01):
  • [30] Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study
    Mei, Heng
    Chen, Xiequn
    Zhou, Jianfeng
    Luo, Jianmin
    Shi, Qingzhi
    Liu, Jing
    Wu, Depei
    Chen, Guoan
    Tai, Yanfei
    Xiong, Junye
    Zou, Jianjun
    Hu, Yu
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)